All Search Results
News Releases
Jan 06, 2026, 18:42 ET Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Built on trust through our fully integrated capabilities – from advanced R&D and in-house manufacturing to a reliable global
More news about: Celltrion
Jan 06, 2026, 18:30 ET Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Jan 06, 2026, 12:15 ET CooperVision bringt weiche MyDay® MiSight® 1 day Kontaktlinsen zur Myopie-Kontrolle auf den Markt
Datei, 2025.Holden BA, Fricke TR, Wilson DA, et al. Globale Prävalenz von Myopie und hoher Myopie und zeitliche Trends von 2000 bis 2050. Ophthalmology. 2016;123(5):1036-1042E. L. Lamoureux et al. Myopia and Quality of Life: Die Singapore Malay Eye Study (SiMES). IOVS 2008;49(13):4469.Chua
More news about: CooperVision, Inc.
Jan 06, 2026, 11:00 ET VivaVision Biotech Receives Positive Written Feedback from FDA - VVN461HD New Drug Application (NDA) Requires Only a "Single Phase III" Pivotal Clinical Study in the U.S. for Non-Infectious Anterior Uveitis Treatment
efficacy, reflecting the clinical development and execution capabilities of the VivaVision team. We look forward to achieving more breakthroughs with ophthalmology drugs represented by VVN461HD in the future. At the same time, we are very grateful for the FDA's recognition of the Phase II clinical trial of
More news about: VivaVision Biotech
Jan 06, 2026, 10:56 ET Společnost CooperVision uvede na trh měkké kontaktní čočky MyDay® MiSight® 1 day pro kontrolu krátkozrakosti
archivu, 2025Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042E. L. Lamoureux et al. Myopia and Quality of Life: The Singapore Malay Eye Study (SiMES). IOVS 2008;49(13):4469.Chua
More news about: CooperVision, Inc.